Metastatic bone disease: Role of transcription factors and future targets

被引:76
作者
Pratap, Jitesh [1 ]
Lian, Jane B. [2 ,3 ]
Stein, Gary S. [2 ,3 ]
机构
[1] Rush Univ, Med Ctr, Dept Anat & Cell Biol, Chicago, IL 60612 USA
[2] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA
[3] Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA
关键词
Runx/AML/Cbfa1; factors; Runx2; MicroRNA; Breast and prostate tumors in bone; Osteolytic disease; Subnuclear targeting; Smads; PROSTATE-CANCER CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; TGF-BETA SUPERFAMILY; GROWTH-FACTOR-BETA; OSTEOBLAST DIFFERENTIATION; GENE-EXPRESSION; MORPHOGENETIC PROTEIN-7; RUNX2; EXPRESSION; TUMOR-GROWTH; BREAST;
D O I
10.1016/j.bone.2010.05.035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Progression of cancer from the earliest event of cell transformation through stages of tumor growth and metastasis at a distal site involves many complex biological processes. Underlying the numerous responses of cancer cells to the tumor microenvironment which support their survival, migration and metastasis are transcription factors that regulate the expression of genes reflecting properties of the tumor cell. A number of transcription factors have been identified that play key roles in promoting oncogenesis, tumor growth, metastasis and tissue destruction. Relevant to solid tumors and leukemias, tissue-specific transcription factors that are deregulated resulting from mutations, being silenced or aberrantly expressed, have been well characterized. These are the master transcription factors of the Runx family of genes, the focus of this review, with emphasis placed on Runx2 that is abnormally expressed at very high levels in cancer cell lines that are metastatic to bone. Recent evidence has identified a correlation of Runx2 levels in advanced stages of prostate and breast cancer and demonstrated that effective depletion of Runx2 by RNA interference inhibits migration and invasive properties of the cells prevents metastatic bone disease. This striking effect is consistent with the broad spectrum of Runx2 properties in activating many genes in tumor cells that have already been established as indicators of bone metastasis in poor prognosis. Potential strategies to translate these findings for therapeutic applications are discussed. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:30 / 36
页数:7
相关论文
共 96 条
  • [11] Bissell MJ, 1999, CANCER RES, V59, p1757S
  • [12] The RUNX genes: Gain or loss of function in cancer
    Blyth, K
    Cameron, ER
    Neil, JC
    [J]. NATURE REVIEWS CANCER, 2005, 5 (05) : 376 - 387
  • [13] Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function
    Brubaker, KD
    Vessella, RL
    Brown, LG
    Corey, E
    [J]. PROSTATE, 2003, 56 (01) : 13 - 22
  • [14] Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases
    Bu, Guojun
    Lu, Wenyan
    Liu, Chia-Chen
    Selander, Katri
    Yoneda, Toshiyuki
    Hall, Christopher
    Keller, Evan T.
    Li, Yonghe
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (05) : 1034 - 1042
  • [15] The critical role of the bone microenvironment in cancer metastases
    Casimiro, Sandra
    Guise, Theresa A.
    Chirgwin, John
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2009, 310 (1-2) : 71 - 81
  • [16] Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development
    Choi, JY
    Pratap, J
    Javed, A
    Zaidi, SK
    Xing, LP
    Balint, E
    Dalamangas, S
    Boyce, B
    van Wijnen, AJ
    Lian, JB
    Stein, JL
    Jones, SN
    Stein, GS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) : 8650 - 8655
  • [17] RUNX3 is multifunctional in carcinogenesis of multiple solid tumors
    Chuang, L. S. H.
    Ito, Y.
    [J]. ONCOGENE, 2010, 29 (18) : 2605 - 2615
  • [18] Integrins in Bone Metastasis Formation and Potential Therapeutic Implications
    Clezardin, P.
    [J]. CURRENT CANCER DRUG TARGETS, 2009, 9 (07) : 801 - 806
  • [19] Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
  • [20] Epithelial-Mesenchymal Transition (EMT) in Tumor-Initiating Cells and Its Clinical Implications in Breast Cancer
    Creighton, Chad J.
    Chang, Jenny C.
    Rosen, Jeffrey M.
    [J]. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2010, 15 (02) : 253 - 260